First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients
![](https://usercontent.one/wp/www.stratipath.com/wp-content/uploads/2023/04/exam-and-CE-ivd-1200px-copy-1024x625.webp)
Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. This paves the way for clinical implementation in the European Union. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E) the software provides novel decision support to clinicians and enables precision medicine for more patients.